Table 3 Presence of symptoms during pyronaridine–artesunate efficacy study for P. vivax in Northwest Ethiopia, 2021
Symptom | Frequency | ||||
|---|---|---|---|---|---|
Day 0 n (%) | Day 1 n (%) | Day 2 n (%) | Day 3 n (%) | Day 7 n (%) | |
Headache | 16 (31.4) | 8 (15.7) | 4 (7.8) | 2 (4.0) | 0 (0.0) |
Cough | 3 (5.9) | 3 (5.9) | 2 (3.9) | 2 (4.0) | 1 (2.0) |
Abdominal pain | 7 (13.7) | 3 (5.9) | 0 (0.0) | 0 (0.0) | 0 (0.0) |
Anorexia | 2 (3.9) | 2 (3.9) | 0 (0.0) | 0 (0.0) | 0 (0.0) |
Vomiting | 2 (3.9) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) |
Nausea | 1 (2.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) |
Diarrhoea | 1 (2.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) |
Total patients assessed | 51 | 51 | 51 | 50 | 50 |